Fibrinolysis parameters in Sudanese women with severe preeclampsia

Background: Although preeclampsia remains a major cause of maternal and fetal morbidity and mortality, its pathogenesis is not fully understood. Coagulation and fibrinolysis changes were suggested to have a role in the pathogenesis of preeclampsia. Objectives: A case-control study was conducted in M...

Full description

Saved in:
Bibliographic Details
Published inHypertension in pregnancy Vol. 35; no. 4; pp. 559 - 564
Main Authors Elzein, Husham O., Muddathir, Abdel Rahim M., Rida, Mohammed, Rayis, Duria A., Elhassan, Elhassan M., Adam, Ishag
Format Journal Article
LanguageEnglish
Published England Taylor & Francis 01.11.2016
Subjects
Adult
Carboxypeptidase B2 - blood
Case-Control Studies
Female
fibrinolysis
Humans
plasminogen
Plasminogen Activator Inhibitor 1 - blood
Plasminogen Activator Inhibitor 2 - blood
Pre-Eclampsia - blood
Pre-Eclampsia - diagnosis
Preeclampsia
Pregnancy
Severity of Illness Index
Sudan
thrombin
Young Adult
fibrinolysis
plasminogen
thrombin
Preeclampsia
Sudan
pregnancy
Online AccessGet full text

Cover

More Information
Summary:Background: Although preeclampsia remains a major cause of maternal and fetal morbidity and mortality, its pathogenesis is not fully understood. Coagulation and fibrinolysis changes were suggested to have a role in the pathogenesis of preeclampsia. Objectives: A case-control study was conducted in Medani Hospital, Sudan, to investigate thrombin-activatable fibrinolysis inhibitor (TAFI) and plasminogen-activated inhibitor (PAI) in women with severe preeclampsia. Obstetrics and medical history was gathered using questionnaire. TAFI, PAI-1, and PAI-2 levels were measured using ELISA. Results: In comparison with the controls, women with severe preeclampsia had significantly higher levels [mean (SD)] of TAFI [3.4 (1.1) vs. 3.0(0.7) ng/ml, P = 0.019], PAI-1 [3.2 (1.3) vs. 2.5(1.0), IU/ml, P = 0.001], and significantly lower PAI-2 level [4.2(1.3) vs. 5.8(2.6) ng/ml, P < 0.001]. In linear regression, severe preeclampsia was significantly associated with TAFI (0.408 ng/ml, P = 0.038), PAI-1 (0.722, IU/ml P = 0.003), and PAI-2 (−1.745, ng/ml, P < 0.001). Conclusion: The current study revealed a significant increase level of TAFI and PAI-1, coupled with a decrease in PAI-2 in women with severe preeclampsia in comparison with the control group.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1064-1955
1525-6065
DOI:10.1080/10641955.2016.1211676